FDA Warning LettersorganizationID: fda-warning-letter-10a106bbd38899dd

"Daniel C. Tarquinio, D.O./Center for Rare Neurological Diseases

Primary Source
FDA WARNING LETTER
Coverage
Global
Risk Tier
High
Last Updated
2026-07-25

Compliance Profile

"Risk Advisory: Records indicate that "Daniel C. Tarquinio, D.O./Center for Rare Neurological Diseases is associated with FDA WARNING LETTER. Source-list verification is recommended."

Banking Impact

Records on FDA WARNING LETTER can trigger enhanced due diligence, compliance holds, counterparty review and documentation requests from banks, investors or procurement teams.

Legal Status

The record should be reviewed against the original source list, jurisdiction and date of publication before decisions are made. Escalation may be required for procurement, onboarding or investor diligence.

Official Source Metadata

Source: FDA Warning Letters
Full Legal Name"Daniel C. Tarquinio, D.O./Center for Rare Neurological Diseases
Source Records
FDA WARNING LETTER
Enforcement TypeFDA Warning Letters
Identifiers2022-04-05 / Clinical Investigator
Risk Topicsreg.action, reg.warn, sector.medical
Official SourceView source record

Associated Subject Network

10 Days Inc d/b/a Pod Juice
FDA WARNING LETTER
10 Days Inc d/b/a Pod Juice
FDA WARNING LETTER
180 Vape E-Cigs & Lounge
FDA WARNING LETTER
1am USA Incorporated dba Pleasure Products USA
FDA WARNING LETTER

Compliance Context Review

Independent Risk Assessment

SIC Group prepares source-backed risk context, exposure memos, and remediation pathways for entities seeking to clarify a public record or counterparty signal.

Source-list verification
Banking and counterparty exposure memo
Regulatory status and remediation triage
Request Risk Assessment
Confidential Review
Export PDFSubscriber Only